Bispecific antibody therapeutics market: Rise in cases cancer to drive the market

Substantial rise in the number of clinical trials intended towards the development of potent and advanced bispecific drugs over the past decade has acted favorably for the global bispecific antibody therapeutics market. These trials have made these drugs a popular as well as a promising candidate for enhanced treatment of various rare medical conditions, especially a variety of cancers. At the present, there are more than 300 drug candidates in the global bispecific antibody therapeutics market. Majority of these are in their pre-clinical or clinical trial stages. Various medical technology providers and drug developers operating within the global bispecific antibody therapeutics market have started collaborating together by signing numerous licensing agreements. These efforts are undertaken to advance the development of promising pipeline drug candidates in the global bispecific antibody therapeutics market.

Researchers are focused in developing bispecific antibodies with unique pharmacological and biological properties that can prove to be promising therapeutic agents in the global bispecific antibody therapeutics market. Enhancements and innovation pertaining to the antibody and proton engineering are expected to pave way for the discovery of more potent and precise target drug candidates in the global bispecific antibody therapeutics market. Usage of these advanced bioengineering techniques has already given rise to the production capability of over 50 new drug formats in the global bispecific antibody therapeutics market in the recent past. However, limitations of these drugs, such as lack of understanding of in-vivo mechanism of drug action and increased patient resistance can hamper the global bispecific antibody therapeutics market in near future. BioSpace